



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 9/38, 15/56	A1	(11) International Publication Number: WO 93/25671 (43) International Publication Date: 23 December 1993 (23.12.93)
(21) International Application Number: PCT/AU93/00294 (22) International Filing Date: 17 June 1993 (17.06.93) (30) Priority data: PL 2985 17 June 1992 (17.06.92) AU PL 3238 29 June 1992 (29.06.92) AU PL 8100 1 April 1993 (01.04.93) AU (71) Applicant (for all designated States except US): COMMON-WEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION [AU/AU]; Limestone Avenue, Campbell, Canberra, ACT 2601 (AU). (72) Inventor; and (75) Inventor/Applicant (for US only) : XUE, Gang, Ping [AU/AU]; 20 Camira Street, St. Lucia, Brisbane, QLD 4067 (AU).		(74) Agent: KELLY, Robin, Thomas; Fisher & Kelly, Level One, 349 Coronation Drive, Milton, QLD 4064 (AU). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: RECOMBINANT XYLANASE (57) Abstract <p>A method of cloning of xylanase clones from an anaerobic rumen fungus including the steps of: (i) cultivation of an anaerobic rumen fungus; (ii) isolating total RNA from the culture in step (i); (iii) isolating poly A⁺ mRNA from the total RNA referred to in step (ii); (iv) constructing a cDNA expression library; (v) ligating cDNA to a bacteriophage expression vector selected from λZAP, λZAPII or vectors of similar properties; (vi) screening of xylanase positive recombinant clones in a culture medium incorporating xylan by detection of xylan hydrolysis; and (vii) purifying xylanase positive recombinant clones. There is also provided xylanase positive recombinant clones produced by the above-mentioned method as well as xylanase positive recombinant clones having the following properties: (i) production of xylan clearing zones in a culture containing xylanase cDNA derived from <i>N. patriciarum</i>; (ii) having activity in hydrolysis of xylan but having no activity in relation to hydrolysis of CMC or crystalline cellulose. There is also provided various cDNA molecules which may be utilised in the above-mentioned method.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

TITLE

"RECOMBINANT XYLANASE"

FIELD OF INVENTION

5 This invention relates to a recombinant xylanase derived from an anaerobic fungus and a method of production of the recombinant xylanase and clones utilised in the method.

BACKGROUND ART

10 Xylan is a major component of hemicellulose and the second major component of plant fibre. Xylan consists of a backbone of β -1,4-linked xylose units. The enzymic cleavage of β -1,4-xylosidic linkages is performed by endo- β -1,4-xylanases (xylanases). Many microorganisms produce extracellular xylanases. In the past decade, many xylanase genes were isolated from lignocellulolytic bacteria, but isolation of xylanase genes from fungi with functional expression in *E. coli* has not
15 been documented prior to this invention.

Lignocellulolytic fungi usually produce more active xylanase than bacteria, in particular, the anaerobic fungus *Neocallimastix patriciarum*, isolated from the sheep rumen, has a high capacity for xylan degradation.

20 Reference may also be made to other prior art which serves as background prior art prior to the advent of the present invention. Such prior art includes:

- (i) Reymond et. al. Gene 110 (1992) 57-63;
- (ii) Wong et. al. Clin. Reviews in Biotechnology 12 413-435
25 (1992);
- (iii) Orpin et. al. Current Microbiology Vol 3 (1979) pp 121-124;
- (iv) Mountfort and Asher in "The Roles of Protozoa and Fungi in Ruminant Digestion" (1989) Pernambul Books (Australia);
- 30 (v) Joblin et. al. FEMS Microbiology Letters 65 (1989) 119-122;

- (vi) Lowe et. al. Applied and Environmental Microbiology June 1987 pp 1210-1215; and
- (vii) Lowe et. al. Applied and Environmental Microbiology June 1987 pp 1216-1223.

5 Cloning of xylanase genes from bacteria can be achieved by isolation of enzymatically active clones from genomic libraries established in *E. coli*. However this approach for isolation of xylanase genes from fungal genomic libraries with functional expression of xylanase is not possible. This is because fungi are eucaryotic
10 microorganisms. Most eucaryotic genes contain introns and *E. coli* is unable to perform post-transcriptional modification of mRNAs in order to splice out introns. Therefore, enzymatically functional protein cannot normally be synthesised in clones obtained from a fungal genomic library.

15 The cDNA cloning approach can be used to overcome the post-transcriptional modification problem in *E. coli*. However, xylanases in fungi are usually glycosylated and glycosylation is often required for biological activity of many glycosylated enzymes. *E. coli* lacks a glycosylation mechanism. This problem can be solved if the cloned gene
20 is transferred to an eucaryotic organism, such as yeast. Other problems which are often encountered in obtaining a biologically functional protein from a cDNA clone in *E. coli* are (i) that many eucaryotic mRNAs contain translational stop codons upstream of the translational start codon of a gene which prevents the synthesis of the cloned protein from the
25 translational start provided in the vector, and (ii) that synthesis of the cloned protein is based on fusion proteins and the biological function of the cloned protein is often adversely affected by the fused peptide derived from the cloning vector.

 Therefore, in the past, researchers in this field employed
30 differential or cross hybridisation, antibody probes or oligonucleotide probes for the isolation of fungal polysaccharide hydrolase cDNA or genomic DNA clones. Relevant publications in this regard include

Reymond et. al. FEMS Microbiology letters 77 (1991) 107-112; Teeri et. al., Biotechnology 1 696-699 (1983); Shoemaker et. al., Biotechnology 1 691-696 (1983); Sims et. al. Gene 74 411-422 (1988); Morosoli and Durand FEMS Microbiology Letters 51 217-224 (1988); and Azevedo et. al. in J. Gen. Microbiol. 136 2569-2576 (1990). However, these methods are very time-consuming, and quite often two stages of intensive cloning work are required for isolation of an enzymatically functional clone. For antibody or oligonucleotide probes, purification of the fungal xylanase is also required. It usually takes more than one year to obtain a functional enzyme clone using the above approaches.

Isolation of fungal xylanase cDNAs by utilising an expression system in *E. coli* has not been reported prior to the advent of this invention probably at least partially due to failure in obtaining enzymatically functional xylanase clones by using improper expression vectors. Selection of expression vector systems is important. If plasmid expression vectors such as pUC vectors are used, and the cloned enzyme is trapped inside the cell, therefore screening for xylanase clones by the convenient xylan-agar plate technique is difficult. Bacteriophage vectors have an advantage in respect to the release of the cloned enzyme into xylan-agar medium due to cell lysis. However, commonly used bacteriophage expression vectors, λ gt11 and its derivatives, have polyclonal sites at the C-terminus of the LacZ peptide. The large part of LacZ peptide fused to the cloned enzyme often adversely affects the cloned enzyme activity.

In specific regard to the abovementioned Reymond et. al. (1991) reference there is described an attempt of molecular cloning of polysaccharide hydrolase (ie. cellulase) genes from an anaerobic fungus which is *N. frontalis*. In this reference a clone from a cDNA library derived from *N. frontalis* hybridized to a DNA probe encoding part of the exo-cellobiohydrolase (CBH 1) gene of *Trichoderma reesei*. However it was subsequently revealed by Reymond et. al. in a personal

communication that the particular cDNA clone obtained from N. frontalis does not encode any polysaccharide hydrolase.

Moreover the Reymond et. al. reference did not describe the production of biologically functional enzymes from these clones.

5 In relation to isolation of a fungal xylanase gene, the only report that exists so far prior to this invention is the abovementioned Morosoli and Durand reference which describes isolation of a xylanase gene from yeast Cryptococcus albidus using differential hybridization techniques. However, this reference does not describe the production of biologically
10 functional enzymes from this xylanase gene.

BROAD STATEMENT OF INVENTION

It is an object of the invention to provide a recombinant xylanase from an anaerobic rumen fungus which may be of use commercially in relation to hydrolysis of xylan.

15 A further object of the invention is to provide a method of cloning of xylanase cDNAs from an anaerobic rumen fungus which may encode the recombinant xylanase of the invention.

A further object of the invention is to provide xylanase clones which may be produced in the abovementioned method.

20 The method of cloning of the invention includes the following steps:

- (i) cultivation of an anaerobic rumen fungus;
- (ii) isolating total RNA from the culture in step (i);
- (iii) isolating poly A⁺ mRNA from the total RNA referred to in
25 step (ii);
- (iv) constructing a cDNA expression library;
- (v) ligating cDNAs to a bacteriophage expression vector selected from λ ZAP, λ ZAP II or vectors of similar properties;
- 30 (vi) screening of xylanase positive recombinant clones in a culture medium incorporating xylan by detection of xylan hydrolysis; and

(vii) purifying xylanase positive recombinant clones.

In step (i) above in relation to preparation of the recombinant xylanase, from anaerobic fungi, particularly alimentary tract fungi, may be cultivated as described hereinbelow. These fungi are strict anaerobes and may be exemplified by *Neocallimastix patriciarum*, *Neocallimastix frontalis*, *Neocallimastix hurleyensis*, *Neocallimastix stanthorpensis*, *Sphaeromonas communis*, *Caecomyces equi*, *Piromyces communis*, *Piromyces equi*, *Piromyces dumbonica*, *Piromyces lethargicus*, *Piromyces mai*, *Ruminomyces elegans*, *Anaeromyces mucronatus*, *Orpinomyces bovis* and *Orpinomyces joyonii*. In regard to the above mentioned anaerobic alimentary tract fungi, *Caecomyces equi*, *Piromyces equi*, *Piromyces dumbonica* and *Piromyces mai* are found in horses and thus are not located in the rumen of cattle like the other fungi described above.

The cultivation may proceed in appropriate culture media containing rumen fluid and also may contain cellulose such as Avicel (ie. a form of microcrystalline cellulose) as a carbon source under anaerobic conditions. After cultivation of the fungi total RNA may be obtained in any suitable manner. Thus initially the fungal cells may be harvested by filtration and subsequently lysed in appropriate cell lysis buffer by mechanical disruption. A suitable RNA preserving compound may also be added to the fungal cells to maintain the RNA intact by denaturing RNases which would otherwise attack the fungal RNA. The total RNA may subsequently be isolated from the homogenate by any suitable technique such as by ultracentrifugation through a CsCl_2 cushion or alternative technique as described by Sambrook et. al. in Molecular Cloning; A Laboratory Manual 2nd Edition Cold Spring Harbor Laboratory Press in 1989. An alternative method for preparation of total fungal RNA to that described above may be based on or adapted from the procedure described in Puissant and Houdebine in Bio-Techniques 148-149 in 1990. Total fungal RNA in this alternative technique may also be isolated from the above homogenate by extraction with phenol

chloroform at pH4 to remove DNA and associated protein. Total RNA obtained was further purified by washing with lithium chloride-urea solution.

5 Poly (A)⁺ mRNA may then be isolated from the total RNA by affinity chromatography on a compound containing multiple thymine residues such as oligo (dT) cellulose. Alternatively a compound containing multiple uracil residues may be used such as poly (U)-Sephadex. The poly (A)⁺ mRNA may then be eluted from the affinity column by a suitable buffer.

10 A cDNA expression library may then be constructed using a standard technique based on conversion of the poly (A)⁺ mRNA to cDNA by the enzyme reverse transcriptase. The first strand of cDNA may be synthesised using reverse transcriptase and the second strand of the cDNA may be synthesised using *E. coli* DNA polymerase I. The cDNA
15 may subsequently be fractionated to a suitable size and may be ligated to the bacteriophage expression vector, preferably λ ZAP or λ ZAPII. The cDNA library may then be amplified after packaging *in vitro*, using any suitable host bacterial cell such as a suitable strain of *E. coli*.

20 The choice of the bacteriophage expression vector in step (v) is important in that such expression vector should include the following features:

- (i) having an *E. coli* promoter;
- (ii) having a translation start codon;
- (iii) having a ribosomal binding site;
- 25 (iv) the fusion peptide derived from the vector should be as small as possible as the biological function of the cloned protein is usually adversely affected by the fused peptide derived from the vector. Therefore the polyclonal sites of the bacteriophage expression vector are suitably located at
30 the N-terminus of lacZ peptides such as in λ ZAPII.

It will be appreciated from the foregoing that if an expression vector is utilis d as described above the chances of obtaining a

biologically functional enzyme is greatly increased. Isolation of many enzymatically functional xylanase clones in the present invention as described hereinafter has proved the efficiency of this approach. To our knowledge this is the first record of isolation of xylanase cDNA clones with functional enzyme activity from anaerobic fungi based upon the expression of recombinant bacteriophage in *E. coli* using an expression vector such as that described above. λ ZAP and λ ZAP II are examples of such expression vectors.

Therefore the term "vectors of similar properties" to λ ZAP or λ ZAPII includes within its scope expression vectors having the abovementioned features (i), (ii), (iii) and (iv).

It is also clear from the product summary which accompanies the λ ZAPII vector as supplied by the manufacturer that in relation to fusion protein expression that such fusion proteins may only be screened with antibody probes. Clearly there was no contemplation that the λ ZAPII vector could be utilised for screening of clones involving enzymic expression on a suitable substrate or any direct screening by biological activity. When it is realised that the present invention involves expression in a bacterial host cell such as *E. coli* of a cDNA of eucaryotic origin (ie. fungal origin) then the novelty of the present invention is emphasised.

The screening of xylanase positive recombinant clones may be carried out by any suitable technique based on hydrolysis of xylan. In this procedure the clones may be grown on culture media incorporating xylan and hydrolysis may be detected by the presence of xylanase-positive plaques suitably assisted by a suitable colour indicator. Xylanase positive recombinant clones may then be purified and the cDNA insert in the clones may then be excised into pBluescript (SK(-)) to provide an expression vector of simplified structure when compared to the λ ZAP II construct which will enhance expression of the xylanase in *E. coli*.

Any suitable *E. coli* promoter may be used in the expression vector described above. Suitable promoters include lacZ, Tac, Bacteriophage T₇ and lambda-P_L.

The recombinant xylanase enzyme may then be characterised and principal features that have been ascertained are as follows:

- (i) the cloned xylanases have high specific activity.
- (ii) the enzyme has no residual activity against cellulose, while many other xylanases possess some cellulase activity. This property of the xylanase is particularly useful in its application to pulp and paper industry to remove xylan and dissociate lignin from plant fibre without damaging cellulose fibre.

The high specific activity of the cloned xylanases is an excellent intrinsic property of this fungal xylanases. The expression level of the present constructs of xylanase cDNAs can be further improved by manipulating the gene and promoters.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Experimental Methods

1. Microbial strains, vectors and culture media.

The anaerobic fungus *Neocallimastix patriciarum* (type species) was isolated from a sheep rumen by Orpin and Munn (1986) in Trans. Br. Mycol. Soc. 86 178-181 and cultivated in the laboratory for many years under selection by lignocellulose substrates. Host strains for cDNA cloning and characterisation of the recombinant xylanases were *E. coli* PLK-F, XL1-Blue and JM83.

The vectors were λZAPII, pBluescript SK(-) (Stratagene). *N. patriciarum* culture was maintained in a medium containing 10% rumen fluid as described by Kemp et. al. (1984). *E. coli* strains were grown in L-broth as described by Sambrook et. al. (1989) for general purposes. The recombinant phage grown in *E. coli* strains using NZY medium according to Stratagene's instructions.

2. General recombinant DNA techniques.

Agarose-gel electrophoresis, transformation of *E. coli* and modification of DNA using restriction enzymes and T4 DNA ligase were as described in Sambrook et. al. above. The alkaline lysis method of Birnboim and Doly as described in Nucl. Acids Res. 7 1513-1523 (1976) as employed to isolate plasmid. In vitro DNA amplification by polymerase chain reaction (PCR) was based on the procedure described by Saiki (1989) in PCR Technology (H.A. Erlich, ed) pp. 7-16, M. Stockton Press, New York.

3. Cultivation of rumen anaerobic fungus, *N. patriciarum* for preparation of RNA.

N. patriciarum was grown in a rumen fluid-containing medium as described in Kemp et. al. J. Gen. Microbiol. 130 27-37 (1984) in the present of 1% Avicel at 39°C and under anaerobic conditions for 48hr (Alternative culture media, such as described by Philips and Gordon in Appln. Environ. Microbiol. 55 1695-1702 in 1989 and Lowe et. al. in J. Gen. Microbiol. 131 2225-2229 in 1985 can be used).

4. Total RNA isolation.

The frozen mycelia were ground to fine powder under liquid nitrogen with a mortar and pestle. 5-10 vol of guanidinium thiocyanate solution (4M guanidinium thiocyanate, 0.5% sodium laurylsarcosine, 25mM sodium citrate, pH7.0, 1mM EDTA and 0.1 M β-mercaptoethanol) was added to the frozen mycelia powder and the mixture was homogenised for 5 min with a mortar and pestle and for further 2 min at full speed using a Polytron homogeniser. Total RNA was isolated from the homogenate by ultracentrifugation through a CsCl cushion (Sambrook et. al., 1989). (An alternative method for preparation of total fungal RNA, such as adaptation of the procedure described by Puissant and Houdebine in Bio-Techniques 148-149 in 1990 can be used).

5. Poly A⁺ mRNA purification.

Poly A⁺ was purified from the total RNA by Oligo (dT) cellulose chromatography (Sambrook et. al., 1989).

6. Construction of a cDNA expression library of *N. patriciarum*.

The cDNA library was constructed, using Stratagene's λ ZAP cDNA synthesis Kit, basically according to the manufacturer's instructions.

5 The procedure is described briefly as follows: PolyA⁺, RNA was converted to the first strand cDNA by reverse transcriptase, using XhoI linker - oligo (dT) primer and 5-methyl dCTP. Double-stranded cDNA was synthesised from the first-strand cDNA by the action of RNase H and DNA polymerase I. After blunting cDNA ends, the cDNA was ligated with EcoR I adaptor, phosphorylated and digested with XhoI to create
10 cDNA with the EcoR I site at 5' region and the XhoI site at 3' region. The cDNA was size-fractionated by 1% low-melting point agarose gel electrophoresis and 1.2-8Kb sizes of the cDNA were recovered by phenol extraction (Sambrook et. al., 1989). The size-fractionated cDNA was then ligated to the EcoRI/XhoI digested λ ZAPII vector.

15 The cDNA library was packaged in vitro and amplified using *E. coli* PLK-F' as plating cells.

7. Screening xylanase-positive recombinant bacteriophage clones.

Recombinant phage were grown in *E. coli* XL1-Blue in 0.7% top agar containing 0.1% xylan and 10mM isopropyl- β -thio-
20 galactopyranoside (IPTG, an inducer for LacZ promoter controlled gene expression). After overnight incubation at 37°C, 0.5% Congo red solution was added over the top agar. After incubation at RT for 15 min, the unbound dye was removed by washing with 1 M NaCl. Xylanase-producing phage plaques were surrounded by yellow haloes
25 against a red background.

The xylanase-positive recombinant phage were purified to homogeneity by replating and rescreening the phage as above for 2-3 times.

30 The cDNA insert in xylanase-positive phage were excised into pBluescript SK (-) using R408 helper phage.

8. Xylanase and related-enzyme assays.

The cloned enzyme extracts from *E. coli* harbouring xylanase-positive recombinant plasmids were prepared by harvesting the cells by centrifugation. The cell pellet was suspended in 25mM Tris-Cl/ 2mM EDTA containing lysozyme (0.25mg/ml) and incubated on ice for 60 mins. After freezing, thawing and homogenisation, the crude cell lysate was used for enzyme assays.

The enzymes were assayed for hydrolysis of xylan or other substrates at 40°C in 50 mM Na-citrate, pH 6.5, except where otherwise indicated in the text. The reducing sugars released from xylan or other plant polysaccharides (Avicel) were measured as described by Lever in Anal. Biochem. 47 273-279 in 1972.

Xylanase activity on Kraft pulp was conducted as follows: Kraft pulp was suspended in tap water, and pH was adjusted to pH 7 with 1M H₂SO₄. The xylanase extract was added to the Kraft pulp suspension and the reducing sugar released was measured as above.

9. DNA sequencing.

Single-stranded plasmid DNA was prepared basically according to Stratagene's protocol. Sequencing of the resultant DNA was based on the protocol recommended by the manufacturer of the T7 DNA polymerase sequencing kit (Promega).

10. Optimisation of growth conditions of pNX-Tac clone.

E. coli strain JM83 harbouring pNX-Tac plasmid grew in LB/Amp_(100µg/ml) at 30°C overnight. One millilitre of the overnight culture was inoculated into 100ml of media as specified in Table 5. IPTG was added at different times of growth. The cultures were grown at 30°C for 17hr, 24hr and 30hr. The cells were harvested for measurement of xylanase yield.

Results and discussion

30 Isolation and partial characterisation of xylanase cDNA clones.

A cDNA library consisting of 10⁶ clones was constructed using mRNA isolated from *N. patriciarum* cells grown with Avicel as sole

carbon source. Thirty-one recombinant bacteriophage, which hydrolysed xylan, were identified after an initial screening of 5×10^4 clones from the library and 16 strongly xylanase-positive phage and two weakly xylanase-positive phage were isolated and purified. Xylanase activity of these recombinant bacteriophage clones was initially analysed by scoring xylan-hydrolysis zones (Fig. 1 and Table 1).

These 16 strongly xylanase positive clones were originally forwarded to Dr H J Gilbert and Dr G P Hazlewood of The University of Newcastle-upon-Tyne and the AFRC Institute of Animal Physiology and Genetics Research in the United Kingdom who carried out further analysis of these clones which included restriction mapping and hybridization analysis as well as sequencing of the longest clone. In this regard reference should be made to the publication "Homologous catalytic domains in a rumen fungal xylanase: evidence for gene duplication and prokaryotic origin" by H J Gilbert, G P Hazlewood, J I Laurie, C G Orpin and G P Xue which is published in *Molecular Microbiology* (1992) 6 (15) 2065-2072. The longest clone referred to in this reference is designated pNX1 and this corresponds to clone pNPX21 described hereinafter. In the Gilbert et. al. reference described above other plasmids pNX2, pNX3, pNX4, pNX5, pNX6 and pNX7 were produced as a result of truncation of pNX1 by restriction enzymes.

The clone corresponding to clone pNX1 in *E. coli* strain XL1-Blue described above has now been deposited at the International Depository ie. Australian Government Analytical Laboratories on June 22, 1992 under accession number N92/27542.

In an attempt to obtain more highly active xylanase clones, further screening of 4×10^5 clones from the library was conducted, which resulted in >200 xylanase-positive clones. Ten highly active clones were isolated and purified. Two of these recombinant bacteriophage clones (ANPX29 and ANPX30) have much stronger xylanase activity than previously isolated high activity clones (see Table 1).

The cDNA inserts encoding *Neocallimastix patriciarum* xylanases were in vivo excised from bacteriophage (λ ZAP11) form into plasmid pBluescript SK⁺ form. Several clones with high xylanase activity were analysed for substrate specificity (four clones presented in Table 2). The xylanases produced by these clones have no activity on carboxymethyl-cellulose (CMC, a substrate for endo-glucanase) or Avicel (Avicel is crystalline cellulose and is a substrate for exo-glucanase). The restriction maps of the representative clones are presented in Fig. 2. It appears that these four xylanase cDNAs have the same restriction pattern but differ in length. pNPX13 and pNPX29 have shorter lengths than pNPX21 but they have much higher activity than pNPX21. Interestingly, pNPX30 has a similar length to pNPX21 but it has about 15-fold higher xylanase activity than pNPX21. Because of the remarkable difference in enzyme activity between pNPX21 and pNPX30, the xylanase cDNA of pNPX30 clone was sequenced. The result shows that DNA sequence of pNPX30 shares the same sequence with pNPX21 in a large part of cDNA, but differ in both the 5' and 3' regions. (Fig. 3). pNPX30 cDNA is not full-length. Interestingly, the N-terminus of pNPX30 xylanase has six repeated arginine/glutamic acid residues (Fig. 4).

The pH and temperature optima of xylanases produced by pNPX21 and pNPX30 were investigated. These enzymes were active in a wide range of pH and preferably at pH 5 - 8. The thermostability of these enzymes was tested at temperatures from 30°C - 60°C. The enzymes are active at 30°C- 55°C and preferably at 40°C - 50°C.

25

Genetic modification of *N. patriciarum* xylanase cDNA

pNPX30 (and pNPX21) contains two large repeated domains. Three main constructs were produced from pNPX30.

30

pNXD-Tac

pNPX30 plasmid (pNPX21 can also be used) was used as a template for in vitro DNA amplification by PCR for construction of pNXD-

Tac using primer I and primer IV (Fig.5). The amplified DNA was digested with EcoR1 and Hind111 and ligated to EcoR1 and Hind111 digested pBTac2 (Boehringer) to produce pNXD-Tac.

5 pNXS-Tac

pNXD-Tac plasmid was digested with Hind111 and blunted by filling-in with Klenow followed by partial digestion with Sca1. After fractionation on LMT agarose gel, the 5.3Kb band was recovered from the gel and ligated to produce the pDGXS construct, which has xylanase activity. pDGXS plasmid was used as a template for in vitro DNA amplification for construction of pNXS-Tac using primer I and primer II (Fig.5). The amplified DNA was digested with EcoR1 and Hind111 and ligated to EcoR1 and Hind111 digested pBTac2 vector to produce pNXS-Tac.

15

pNX-Tac

pNPX30 plasmid (pNPX21 or other xylanase cDNAs listed in Fig.2 can be used) was digested with Rsa1 and a 709bp fragment as indicated in Fig.5 was isolated after fractionation on agarose gel electrophoresis. The 709 fragment was ligated to Sma1 and Pst1 digested pUC18 (Pst1 end was blunted with T4 DNA polymerase). This construct is designated pNXP2 and the xylanase activity of this construct with the right orientation of truncated xylanase cDNA from pNPX30 confirmed that this fragment of the cDNA encodes a catalytically functional domain. Two oligonucleotide primers, primer III and primer IV, (Fig.5) were then designed for PCR amplification of the pNXP2 xylanase cDNA insert. The PCR amplified fragment was digested with EcoR1 and Hind111 and ligated to EcoR1 and Hind111 digested pBTac2 vector to produce pNX-Tac.

30

These constructs are all modified at the N-terminal sequence of the truncated xylanase cDNA and a translational stop codon (TAA) was introduced into the end of the truncated xylanase coding region. The

expression of xylanase was controlled by the Tac promoter (Fig.6) and xylanases in these constructs are synthesised as nonfusion proteins. The modified xylanase cDNA sequence in pNX-Tac is shown in Fig 7.

The specific activity of crude xylanase preparations of pNXD-Tac, pNXS-Tac and pNX-Tac clones were 228, 124 and 672 U/mg of total cellular protein of *E.coli* respectively, measured in 50mM Na-citrate buffer (pH6) and at 50°C (Fig.5). The xylanase synthesised by the clone pNX-Tac was found mainly in the cell pellet, but a small amount of xylanase (about 5%) was released into the culture medium (Table 3). The pNX-Tac xylanase has a temperature optimum at 50°C and retained >80% of the maximum activity from 40°C to 55°C, and 55% of the activity at 60°C (Fig.8). pNX-Tac xylanase has a broad pH range (Fig 9) and is most active at pH5-7.5, 50% at pH8.5 and 20% at pH9.5. The pNX-Tac xylanase has a high activity in the release of reducing sugar from Kraft pulp at 55°C and in tap water (pH was adjusted to pH7 with H₂SO₄, see Fig.8) and remains active in the hydrolysis of xylan from the pulp at 55°C and pH7 for at least 3hr (Fig.10) The pNX-Tac xylanase is able to hydrolyse a significant amount of xylan from Eucalypt and Pine Kraft pulps (Table 4).

20

Optimisation of growth conditions pNX-Tac clone.

In order to reduce the cost of xylanase production, growth conditions of *E. coli* strain JM83 harbouring pNX-Tac plasmid were investigated. Table 5 shows that on a laboratory scale pNX-Tac clone preferably grows in LBMG medium at 30°C for 24 hr, which produced 2-fold higher xylanase yield than LBS. IPTG is preferably added at the beginning of the cultivation (Table 6).

Xylanase has many industrial applications, such as the pulp and paper industry, food processing, the feed industry and animal production industry. The enzymes produced by these recombinant xylanase clones have no cellulase activity and have the pH and temperature profile (especially the genetically modified xylanase clone, pNX-Tac) fitted to

30

conditions used for the enzymatic pre-treatment of pulp. Therefore it is believed that the xylanases of the present invention are applicable to the paper and pulp industry.

5 Sandoz Products Pty Ltd, in the USA, have conducted practical trials using their product, Cartazyme, which is a fungal xylanase (crude), active at 30°C-55°C, pH 3 to 5, and contains 2 xylanases, and have found that a 25-33% reduction in chlorine is possible using 1U xylanase/g pulp. Also the product is brighter than when chemicals alone are used. Another advantage of the xylanase is that it is specific
10 whereas chemicals can attack the cellulose at low lignin contents, leading to reduced fibre strength and other undesirable physical characteristics. It is therefore clear that xylanases could become more important in pulp bleaching and recombinant ones particularly so because of their specificity and high level of expression. In particular, the pNX-Tac xylanase is very active in hydrolysing of xylan from Kraft pulps.
15

It is also believed that the xylanase of the invention could find a valuable application in the sugar industry and in relation to the treatment of bagasse or other products containing xylan for more efficient disposal as well as for the treatment of feedstock to improve nutritional value.
20 The genetically modified xylanase gene can also be used for modification of rumen bacteria to improve plant fibre utilization by ruminants.

It therefore will be apparent from the foregoing that the invention includes within its scope not only the recombinant xylanase described above but also xylanases derived from other anaerobic fungi as described
25 above which may be prepared by the methods described herein.

The invention also includes within its scope:

- (i) DNA sequences derived from these xylanase cDNAs (particularly the sequences in pNPX30, pNXD-Tac, pNXS-Tac and pNX-Tac) and DNA sequences capable of hybridising thereto using a
30 standard nucleic acid hybridisation technique as described in Sambrook et. al. (1989);

- (ii) a DNA construct containing a DNA sequence as in (i) operably linked to regulatory regions capable of directing the expression or over-expression of a polypeptide having xylanase activity in a suitable expression host;
- 5 (iii) a transformed microbial host capable of the expression or over-expression of the fungal xylanase, harbouring the above mentioned xylanase constructs;
- (iv) a polypeptide having xylanase activity produced by expression using a microbial host as in (iii);
- 10 (v) amino acid sequence derived from these xylanases, truncations and modifications therefrom, by one skilled in the art.

Plasmid pNX-Tac in *E. coli* strain JM83 has been deposited at the International Depository ie. Australian Government Analytical Laboratories 17 March 1993 under accession number N93/12211.

- 15 In summary the cloning method of the invention is based upon obtaining a large number of recombinant xylanase clones with strong xylanase activity from an anaerobic rumen fungus such as *N. patriciarum* which were functionally expressed in *E. coli*. This approach for isolation of fungal xylanase or other plant polysaccharide hydrolases such as
- 20 cellulases has not been documented prior to this invention. The approach used in this invention is very efficient and requires only a single cloning step to obtain biologically functional recombinant xylanases from an anaerobic fungus. Therefore it takes much less time to obtain biologically functional xylanase clones from a fungal source compared to
- 25 previous approaches for isolation of plant polysaccharide hydrolases from fungi which are described in the prior art discussed above.

The term "essentially" as used in the appended claims includes within its scope sequences having 70-100% identity to those sequences shown in Figs. 3, 4, 5 and 7.

Table 1

Xylanase activity of recombinant Bacteriophage clones on Xylan - plat assay

Xylan - clearing zone	
λNPX11	L
λNPX12	S
λNPX13	L+++ (9mm)
λNPX14	L
λNPX15	L+
λNPX16	L
λNPX17	S (4mm)
λNPX18	L+
λNPX19	L
λNPX20	L
λNPX21	L+ (7mm)
λNPX22	L
λNPX23	L
λNPX24	L
λNPX25	L+
λNPX26	L++ (8.5mm)
λNPX27	L
λNPX28	L+
λNPX29	L++++ (10.5mm)
λNPX30	L++++ (10.5mm)

L: Large size

S: Small size

Values in parenthesis is diameter of zone.

λNPX11-28 were isolated from initial screening.

λNPX29 and λNPX30 were isolated after further screening of *N.patricianum* cDNA library.

Table 2

Specific activity of the cloned xylanases from *N. patriciarum*

	Specific activity (U/mg protein)		
	Xylan	CMC*	Crystalline cellulose
pNPX13	41.6	0	0
pNPX21	7.8	0	0
pNPX29	73.5	0	0
pNPX30	113	0	0

* Analysed by CMC plate assay.

Crude enzyme extracts were used for enzyme assay. The reactions were carried out at 40°C in 50 mM Na-citrate, pH6.5, containing 0.25% xylan or 1% Avicel.

Table 3

Specific activity of pNX-Tac xylanase.

Substrate	Cell pellet		Culture supernant U/ml culture
	U/mg protein	U/ml culture	
Xylan	672	726	23
CMC*	0		
Crystalline cellulose (Avicel)	0		

* Analysed on CMC - plate.

E.coli strain JM83 harbouring pNX-Tac plasmid was grown in L-broth at 30°C for 17hrs.

Xylanase activity was measured in 50mM Na-citrate pH6 containing 0.25% Xylan at 50°C and the reducing sugar released was measured as described in the method.

Table 4

Reducing sugar released from Kraft pulp.

mg reducing sugar released/g dry pulp		
Xylanase $\mu\text{l/g}$ dry pulp	Eucalypt pulp	Pine pulp
0	0	0
10 μl	11.9	6.97
100 μl	28.9	9.53

The crude xylanase extract from pNX-Tac clone was incubated with 6%(W/V) pulp suspension in tap water at pH 7.0. The hydrolysis was carried out at 52°C for 3 hours.

Table 5

Optimisation of growth conditions of *E.coli* JM83 harbouring pNX-Tac plasmid.

	IPTG	cell mass at 24hr (g/Litre)	Xylanase yield		
			(Relative activity)		
			17hr	24hr	30hr
LBS	0.5mM	10		100%	100%
LBSG		11		55%	55%
LBMG	0.1mM	22		168%	168%
	0.5mM	22	151%	200%	200%
	2.5mM	22		190%	190%
LBMHG	0.5mM	20		110%	110%

E.coli strain JM83 harbouring pNX-Tac plasmid was grown in the specified media containing 50µg/ml Amp at 30°C and IPTG was added at the beginning of the cultivation.

Composition of Media, per litre.

LBS: Bacto-tryptone 10g
 Bacto-yeast ext. 5g
 NaCl 10g
 Sucrose (0.4%) 4g
 pH 7.2

LBSG: LBS plus
 0.4% Glucose

LBMG: Bacto-tryptone 5g
 Bacto-yeast ext. 3g
 NaCl 0.5g
 Na₂HPO₄·12H₂O 15.1g
 KH₂PO₄ 3g
 NH₄Cl 1g
 Casamino acids 5g
 Sucrose 6g
 CaCl₂ (100mM) 1ml
 MgSO₄ (1M) 2ml
 Glucose 4g
 pH 7.2

LBMHG: LBMG plus
 glucose increased to 1% by
 adding an extra 6g glucose.

Table 6**Optimisation of Induction time of pNX-Tac clone.**

IPTG added at	Xylanase yield (relative activity)
0hr	100%
8hr	82%
16hr	40%

E.coli strain JM83 harbouring pNX-Tac plasmid was grown in LBMG containing 50µg/ml Amp and 0.5 mM IPTG at 30°C for 24 hours.

LEGENDS

Figures 1(a), 1(b), 1(c) and 1(d)

Xylan-clearing zones of recombinant bacteriophage clones containing xylanase cDNAs for *N. patriciarum* concerning clones λ NPX13, λ NPX17,

5 λ NPX21 and λ NPX26 respectively.

Figure 2

Restriction maps of the highly active xylanase clones isolated from *Neocallimastix patriciarum* cDNA library.

Abbreviations for restriction enzymes:

10 B, BstXI; E, EcoRI; H, HpaI; K, KpnI; P, PvuII; S, SacI; Sc, Scal; X, XhoI.

Figure 3

The DNA sequence of pNPX30 xylanase cDNA. The sequence typed in small letters comes from the pBluescript SK vector.

Figure 4

15 The amino acid sequence of pNPX30 xylanase. The amino acid residues underlined come from the N-terminus of LacZ peptide and encoded by polylinker sequence in the pBluescript SK vector.

Figure 5

The genetically modified constructs of the xylanase cDNA

20 vector: pBTac₂

primers:

PI: 5'-CGGAATTCATG GCT AGC AGA TTA ACC GTC GGT AAT GGT C

PII: 5'-ATACG TAAGC TTAAA CAGTA CCAGT GGAGG TAG

PIII: 5'-CGGAA TTCAT GGCTA GCAAT GGTA AAAGT TTA CT G

PIV: 5'-ATACG TAAGC TTAAC GAGGA GCGGC AGAGG TGG

Abbreviations for restriction enzymes:

B, BstX I; E, EcoR I; H, Hpa I; K, Kpn I; P, Pvu II; S, Sac I; Sc, Sca I; X,

5 Xho I.

Figure 6

pNX-Tac construct

Figure 7

The sequence of the modified xylanase cDNA in pNX-Tac

10 Figure 8

Effect of incubation temperature on the activity of pNX-Tac xylanase.

Xylanase assays were performed in 50 mM Na-citrate (pH7) and 0.25% (w/v) xylan at the various temperatures for 30 min.

Figure 9

15 Effect of pH on the activity of pNX-Tac xylanase.

Xylanase assays were performed at 50 C in 50 mM Na-citrate (pH5-7) or 25 mM Tris-Cl / 50 mM NaCl (pH7.5-9.5) with 0.25% xylan for 30 min. The pHs of the buffers were measured at room temperature.

Figure 10

20 Time course of pNX-Tac xylanase activity on eucalypt Kraft pulp.

Hydrolysis was carried out at 55°C in tap-water suspended pulp at pH 7.0.

CLAIMS:

1. A method of cloning of xylanase clones from an anaerobic rumen fungus including the steps of:
 - (i) cultivation of an anaerobic rumen fungus;
 - (ii) isolating total RNA from the culture in step (i);
 - (iii) isolating poly A⁺ mRNA from the total RNA referred to in step (ii);
 - (iv) constructing a cDNA expression library;
 - (v) ligating cDNA to a bacteriophage expression vector selected from λ ZAP, λ ZAPII or vectors of similar properties;
 - (vi) screening of xylanase positive recombinant clones in a culture medium incorporating xylan by detection of xylan hydrolysis; and
 - (vii) purifying xylanase positive recombinant clones.
2. A method as claimed in claim 1 wherein the expression vector is λ ZAPII.
3. A method as claimed in claim 1 wherein the detection of enzyme hydrolysis is carried out using a colour indicator Congo red.
4. A method as claimed in claim 1 wherein after production of xylanase positive clones the cDNA insert in such clones were excised into p Bluescript SK(-) using helper phage.
5. A method as claimed in claim 4 wherein the helper phage is R408 helper phage.
6. Xylanase positive recombinant clones produced by the method of claim 1.
7. Xylanase positive recombinant clones having the following properties:
 - (i) production of xylan clearing zones in a culture containing xylanase cDNA derived from N. patriciarum;
 - (ii) having activity in hydrolysis of xylan but having no activity in relation to hydrolysis of CMC or crystalline cellulose.

8. Recombinant xylanase clone pNPX21 deposited at the Australian Government Analytical Laboratories on June 22, 1992 under accession number N92/27542.
 9. An isolated DNA molecule including a DNA sequence essentially corresponding to pNPX30 xylanase cDNA as shown in FIG 3 including DNA sequences capable of hybridizing thereto.
 10. A polypeptide including amino acid sequence of pNPX30 xylanase essentially as shown in FIG 4.
 11. An isolated DNA molecule including a DNA sequence corresponding to pNXD-Tac essentially as shown in FIG 5 including DNA sequences capable of hybridizing thereto.
 12. An isolated DNA molecule including a DNA sequence corresponding to pNXS-Tac essentially as shown in FIG 5 including DNA sequences capable of hybridizing thereto.
 13. An isolated DNA molecule including a DNA sequence corresponding to pNX-Tac essentially as shown in FIG 5 including DNA sequences capable of hybridizing thereto.
 14. Primer PI shown in FIG 5.
 15. Primer PII shown in FIG 5.
 16. Primer PIII shown in FIG 5.
 17. Primer PIV shown in FIG 5.
 18. An isolated DNA molecule including a DNA sequence essentially as shown in FIG 7 including DNA sequences capable of hybridizing thereto.
 19. Xylanases produced from the recombinant xylanase clones of claim 6.
 20. Xylanases produced from the recombinant xylanase clones of claim 7.
 21. A DNA construct containing a DNA sequence as claimed in claim 9 operably linked to regulatory regions capable of directing the expression or over-expression of a polypeptide having xylanase activity in a suitable expression host.
-

22. A DNA construct containing a DNA sequence as claimed in claim 11 operably linked to regulatory regions capable of directing the expression or over-expression of a polypeptide having xylanase activity in a suitable expression host.
23. A DNA construct containing a DNA sequence as claimed in claim 12 operably linked to regulatory regions capable of directing the expression or over-expression of a polypeptide having xylanase activity in a suitable expression host.
24. A DNA construct containing a DNA sequence as claimed in claim 13 operably linked to regulatory regions capable of directing the expression or over-expression of a polypeptide having xylanase activity in a suitable expression host.
25. A DNA construct containing a DNA sequence as claimed in claim 18 operably linked to regulatory regions capable of directing the expression or over-expression of a polypeptide having xylanase activity in a suitable expression host.
26. A transformed microbial host capable of the expression or over expression of fungal xylanase harbouring the xylanase construct of claim 21.
27. A transformed microbial host capable of the expression or over expression of fungal xylanase harbouring the xylanase construct of claim 22.
28. A transformed microbial host capable of the expression or over expression of fungal xylanase harbouring the xylanase construct of claim 23.
29. A transformed microbial host capable of the expression or over expression of fungal xylanase harbouring the xylanase construct of claim 24.
30. A transformed microbial host capable of the expression or over expression of fungal xylanase harbouring the xylanase construct of claim 25.

31. A polypeptide having xylanase activity produced by expression using a microbial host of claim 26.
32. A polypeptide having xylanase activity produced by expression using a microbial host of claim 27.
33. A polypeptide having xylanase activity produced by expression using a microbial host of claim 28.
34. A polypeptide having xylanase activity produced by expression using a microbial host of claim 29.
35. A polypeptide having xylanase activity produced by expression using a microbial host of claim 30.
36. A polypeptide including amino acid sequences derived from the polypeptide of claim 31 including truncated and modified forms thereof.
37. A polypeptide including amino acid sequences derived from the polypeptide of claim 32 including truncated and modified forms thereof.
38. A polypeptide including amino acid sequences derived from the polypeptide of claim 33 including truncated and modified forms thereof.
39. A polypeptide including amino acid sequences derived from the polypeptide of claim 34 including truncated and modified forms thereof.
40. A polypeptide including amino acid sequences derived from the polypeptide of claim 35 including truncated and modified forms thereof.
41. Plasmid pNX-Tac lodged at the Australian Government Analytical Laboratories on March 17, 1993 under accession number N93/12211.
42. An isolated cDNA molecule which encodes a functional Neocallimastix xylanase.
43. An isolated cDNA molecule which encodes a functional Neocallimastix patriciarum xylanase.

44. A transformed microbial host capable of the expression or over expression of fungal xylanase harbouring the cDNA molecule of claim 42.
 45. A transformed microbial host capable of the expression or over expression of fungal xylanase harbouring the cDNA molecule of claim 43.
 46. A polypeptide having xylanase activity produced by expression using the microbial host of claim 44.
 47. A polypeptide having xylanase activity produced by expression using the microbial host of claim 45.
 48. Amino acid sequences derived from the peptide of claim 46 including truncated and modified forms thereof.
 49. Amino acid sequences derived from the peptide of claim 47 including truncated and modified forms thereof.
-




FIG. 1(a)




FIG. 1(b)




FIG. 1(c)




FIG. 1(d)

FIGURE 1




FIGURE 2

1	atgaccatga	ttacgccaag	ctcgaaatta	accctcacta	aaggggaacaa
51	aagctggagc	tccaccgcgg	tggcggccgc	tctagaacta	gtggatcccc
101	cgggctgcag	gaattcggca	cgagGAGAGA	GAGAGAGAGA	GAGAGAGAGA
151	GAGAGAGAGA	GAGCCCAATG	GGGTGGAGGT	GGTGCCTCTG	CTGGTCAAAG
201	ATTAACCGTC	GGTAATGGTC	AAACCCAACA	TAAGGGTGTA	GCTGATGGTT
251	ACAGTTATGA	AATCTGGTTA	GATAACACCG	GTGGTAGTGG	TTCTATGACT
301	CTCGGTAGTG	GTGCAACCTT	CAAGGCTGAA	TGGAATGCAT	CTGTTAACCG
351	TGGTAACTTC	CTTGCCCGTC	GTGGTCTTGA	CTTCGGTTCT	CAAAAGAAGG
401	CAACCGATTA	CAGCTACATT	GGATTGGATT	ATACTGCAAC	TTACAGACAA
451	ACTGGTAGCG	CAAGTGGTAA	CTCCCGTCTC	TGTGTATACG	GTGGTTCCA
501	AAACCGTGGA	GTTCAAGGTG	TTCCATTGGT	AGAATACTAC	ATCATTGAAG
551	ATTGGGTTGA	CTGGGTCCA	GATGCACAAG	GTAGAATGGT	AACCATTGAT
601	GGAGCTCAAT	ATAAGATTTT	CCAAATGGAT	CACACTGGTC	CAACTATCAA
651	TGGTGGTAGT	GAAACCTTTA	AGCAATACTT	CAGTGTCCGT	CAACAAAAGA
701	GAACTTCTGG	TCATATTACT	GTCTCAGATC	ACTTTAAGGA	ATGGGCCAAA
751	CAAGGTTGGG	GTATTGGTAA	CCTTTATGAA	GTTGCTTTGA	ACGCCGAAGG
801	TTGGCAAAGT	AGTGGTATAG	CTGATGTCAC	CAAGTTAGAT	GTTTACACAA
851	CCCAAAAAGG	TTCTAATCCT	GCCCCTACCT	CCACTGGTAC	TGTTCCAAGC
901	AGTCTCTGCTG	GTGGAAGTAC	TGCCAATGGT	AAAAAGTTTA	CTGTCGGTAA
951	TGGACAAAAC	CAACATAAGG	GTGTCAACGA	TGGTTTCAGT	TATGAAATCT
1001	GGTTAGATAA	CACTGGTGGT	AACGGTTCTA	TGACTCTCGG	TAGTGGTGCA
1051	ACTTTC AAGG	CTGAATGGAA	TGCAGCTGTT	AACCGTGGTA	ACTTCCTTGC
1101	CCGTCGTGGT	CTTGACTTCG	GTTCTCAAAA	GAAGGCAACC	GATTACGACT
1151	ACATTGGATT	AGATTATGCT	GCTACTTACA	AACAAACTGC	CAGTGCAAGT
1201	GGTAACTCCC	GTCTCTGTGT	ATACGGATGG	TTCCAAAACC	GTGGACTTAA
1251	TGGCGTTCCT	TTAGTAGAAT	ACTACATCAT	TGAAGATTGG	GTTGACTGGG
1301	TTCCAGATGC	ACAAGGAAAA	ATGGTAACCA	TTGATGGAGC	TCAATATAAG
1351	ATTTTCCAAA	TGGATCACAC	TGGTCCAAC	ATCAATGGTG	GTAGTGAAAC

4/11

1401				
CTTTAAGCAA	TACTTCAGTG	TCCGTCAACA	AAAGAGAACT	TCTGGTCATA
1451				
TTACTGTCTC	AGATCACTTT	AAGGAATGGG	CCAAACAAGG	TTGGGGTATT
1501				
GGTAACCTTT	ATGAAGTTGC	TTTGAACGCC	GAAGGTTGGC	AAAGTAGTGG
1551				
TGTTGCTGAT	GTCACCTTAT	TAGATGTTTA	CACAACTCCA	AAGGGTTCTA
1601				
GTCCAGCCAC	CTCTGCCGCT	CCTCGTACTA	CTACCCGTAC	TACTACTCGT
1651				
ACCAAGTCTC	TTCCAACCAA	TTACAATAAG	TGTTCTGCTA	GAATTACTGC
1701				
TCAAGGTTAC	AAGTGTTGTA	GCGATCCAAA	TTGTGTTGTT	TACTACACTG
1751				
ATGAGGATGG	TACCTGGGGT	GTTGAAAACA	ACGACTGGTG	TGGTTGTGGT
1801				
GTTGAACAAT	GTTCTTCCAA	GATCACTTCT	CAAGGTTACA	AGTGTTGTAG
1851				
CGATCCAAAT	TGCGTTGTTT	TCTACACTGA	TGACGATGGT	AAATGGGGTG
1901				
CTGAAAACAA	CGACTGGTGT	GGTTGTGGTT	TCTAAGCAGT	AAAATACTAA
1951				
TTAATAAAAA	ATTAAAGAAT	TATGAAAAT	TTAAATTTAA	AAATTTAAAA
2001				
GAATTATGAA	AAATTTAAAT	TTAAAAATTT	AAAAAAAAC	AATTTAGTAA
2051				
AAAATTAAAG	AATTATTGAA	AATTTTAAAT	GTAAAAATTT	AAAAAATACA
2101				
AATTTGTAAA	AAAAAATGAA	AGAATTATGA	AAAATTAAAA	TGTAAAAGTT
2151				
TAAAAAATAC	AAATTTGTAA	GAAAAATAAA	GAATTATAAA	AAAAATAAAG
2201				
AATTATGAAA	AATTTAAATG	TAAAAATTTA	AAAATATAAT	TTTTAAAATA
2251				
ATAAGAATT	ATGAAAAATT	AAATATAAAA	ATATAAAAGT	GTTGATTTAG
2301				
TAAAAAATAA	AAAATTATGA	AAATTTTAAA	TATAAAAATT	AAAAAATATT
2351				
GATTTAGTAG	AAAAATAAAA	AATTATGAAA	AATTTAAAAT	TTATAAAAAA
2401				
TATAAATTTG	TAAAAATTTA	AATGAAAAAT	TTAAAAATAT	AATTTTTAAA
2451				
ATAATAAAGA	ATTATGAAAA	ATTAAATATA	AAAAAAAAAA	AAAAAAAAAA
2501				
AAA				

FIGURE 3

MTMITPSSSKLTLTTKGNKSWSSSTAVAAALELV
DPPGCRNSARGERERERERERERERERAQWGGGGA
 SAGQRLTVGNNGQTQHKGVADGYSEIWL DNT
 GSGSMTLGSGATFKA EWNASVNRGNFLARR
 GLDFGSQKKATDYSYIGLDYATYRQTGSAS
 GNSRLCVYGWFQNRGVQGVPLVEYYIIEDWV
 DWVPDAQGRMVTIDGAQYKIFQMDHTGPTIN
 GGSETFKQYFSVRQQKRTSGHITVSDHFKEW
 AKQGWGIGNLYEVALNAEGWQSSSGIADVTKL
 DVYTTQKGSNPAPTSTGTVPSSSAGGSTANG
 KKFTVGNGQNQHKG VNDGFSYEIWL DNTG GN
 GSMTLGSGATFKA EWNAAVN RGNFLARRGLD
 FGSQKKATDYDYIGLDYAATYKQTASASGNS
 RLCVYGWFQNRGLNGVPLVEYYIIEDWVDWV
 PDAQGKMVTIDGAQYKIFQMDHTGPTINGGS
 ETFKQYFSVRQQKRTSGHITVSDHFKEWAKQ
 GWGIGNLYEVALNAEGWQSSSGVADVTL LLDVY
 TTPKGS SPATSAAPRTTTRTTTRTKSLPTNY
 NKCSARITAQGYKCCSDPNCVVYYTDEDGTW
 GVEN NDWCGCGVEQCSSKIT SQGYKCCSDP
 NCVVFYTD DDDGKWGAENNDWCGCGF

FIGURE 4

SUBSTITUTE SHEET




Figure 5




Figure 6

ATGGCTAGC AATGGTAAAAAGT
M A S N G K K

TTACTGTCGGTAATGGACAAAACCAACATAAGGGTGTCAACGATGGTTTCAGTTATGAAA
F T V G N G Q N Q H K G V N D G F S Y E

TCTGGTTAGATAACACTGGTGGTAACGGTTCTATGACTCTCGGTAGTGGTGCAACTTTCA
I W L D N T G G N G S M T L G S G A T F

AGGCTGAATGGAATGCAGCTGTTAACCGTGGTAACCTTCCTTGCCCGTCGTGGTCTTGACT
K A E W N A A V N R G N F L A R R G L D

TCGGTTCTCAAAAGAAGGCAACCGATTACGACTACATTGGATTAGATTATGCTGCTACTT
F G S Q K K A T D Y D Y I G L D Y A A T

ACAAACAACTGCCAGTGCAAGTGGTAACTCCCGTCTCTGTGTATACGGATGGTTCCAAA
Y K Q T A S A S G N S R L C V Y G W F Q

ACCGTGGACTTAATGGCGTTCCTTTAGTAGAATACTACATCATTGAAGATTGGGTTGACT
N R G L N G V P L V E Y Y I I E D W V D

GGGTTCCAGATGCACAAGGAAAAATGGTAACCATTGATGGAGCTCAATATAAGATTTTCC
W V P D A Q G K M V T I D G A Q Y K I F

AAATGGATCACACTGGTCCAACCTATCAATGGTGGTAGTGAAACCTTTAAGCAATACTTCA
Q M D H T G P T I N G G S E T F K Q Y F

GTGTCCGTCAACAAAAGAGAACTTCTGGTCAATATTACTGTCTCAGATCACTTTAAGGAAT
S V R Q Q K R T S G H I T V S D H F K E

GGGCCAAACAAGGTTGGGGTATTGGTAACCTTTATGAAGTTGCTTTGAACGCCGAAGGTT
W A K Q G W G I G N L Y E V A L N A E G

GGCAAAGTAGTGGTGTTCCTGATGTCACCTTATTAGATGTTTACACAACCTCCAAAGGGTT
W Q S S G V A D V T L L D V Y T T P K G

CTAGTCCAGCCACCTCTGCCGCTCCTCGT TAA
S S P A T S A A P R

Figure 7




FIGURE 8




FIGURE 9





FIGURE 10

A. CLASSIFICATION OF SUBJECT MATTER Int. CL ⁵ C12N 9/38, C12N 15/56 According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC: C12N, Derwent Databases: WPAT, Chem Abstracts. K yw rds: as below. Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched IPC: AU database C12N 9/38, C12N 15/56 Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) Derwent Databases: WPAT, keywords: xylan:, fung:, C12N/IC; CASM and Biotechnology Abstracts, keywords: xylan:, fung:, recombin:, DNA, gene:, not P/DT STN Database: oligonucleotide primers as defined in claims 14-17					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.			
P,X Y	Australian Microbiologist, Vol. 13(3), issued July 1992 by the Australian Society for Microbiology (Parkville, Vic.), G.P. Xue et al, "Expression of a multi-functional cellulolytic cDNA from the rumen fungus <u>Neocallimastix patriciarum</u> in <u>E. coli</u> , page A22	42-47 1,6,7,19			
P,Y	Can. J. Microbiol., Vol. 39(1), issued January 1993, J.M. Tamblyn Lee et al, "Cloning of a xylanase gene from the ruminal fungus <u>Neocallimastix patriciarum</u> 27 and its expression in <u>Escherichia coli</u> , pages 134-139	1,6,7,19,42-47			
P,Y	Biosci. Biotech. Biochem, Vol. 56(6), issued 1992 by the Society for Bioscience, Biotechnology and Agriculture (Tokyo), K. Ito et al, "Cloning and sequencing of the xynA gene encoding xylanase A of <u>Aspergillus kawachii</u> , pages 906-912	1,6,7,19,42-47			
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. </div> <div style="width: 45%;"> <input checked="" type="checkbox"/> See patent family annex. </div> </div>					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;"> <p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 33%; vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </td> <td style="width: 33%;"></td> </tr> </table>			<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>	
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>				
Date of the actual completion of the international search 7 September 1993 (07.09.93)		Date of mailing of the international search report 15 OCT 1993 (15.10.93)			
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No. (06) 2853929		Authorized officer <div style="text-align: center; font-size: 1.2em;">  </div> IAN ROSE Telephone No. (06) 2832494			

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
P,Y	Bi sci. Biotech. Biochem, Vol. 56(8), issued 1992 by the Society for Bi science, Biotechnology and Agriculture (Tokyo), K. Ito et al, "Cloning and sequencing of the xynC gene encoding acid xylanase of <u>Aspergillus kawachii</u> , pages 1338-1340	1,6,7,19,42-47
P,Y	FEMS Microbiology Reviews, Vol. 104 (1 and 2), issued January 1993 by the Federation of European Microbiological Societies (Elsevier, Amsterdam), J.A. Thomson, "Molecular biology of xylan degradation", pages 65-82	1
A	AU,A,80668/91 (Unilever PLC) 26 December 1991 (26.12.91)	

